Painchek (ASX:PCK) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 09, 2026)


ASX:PCK Painchek Ltd ASX:PCK
50 GF Score
Price A$0.11
GF Value A$0.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Painchek 5-Year Yield-on-Cost %?

Painchek ASX:PCK -4.35% 50 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. GuruFocus rates ASX:PCK with a GF Score™ of 50/100 and a GF Value™ of A$0.40 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 280 Healthcare Providers & Services companies, Painchek ranks worse than 357142.5% on this metric.

Painchek's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Painchek's 5-Year Yield-on-Cost % or its related term are showing as below:



ASX:PCK's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.935
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Painchek  (ASX:PCK) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Painchek 5-Year Yield-on-Cost % Related Terms


ASX:PCK vs VEEV, BTSG, TEM: 5-Year Yield-on-Cost % Comparison

For the Health Information Services subindustry, Painchek's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Painchek 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Painchek's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Painchek's 5-Year Yield-on-Cost % falls into.


ASX:PCK
50GF Score
Painchek Ltd ASX:PCK
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Painchek 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Painchek is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Painchek (ASX:PCK) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Painchek and its competitors. According to the industry distribution chart, Painchek ranks #999999 out of 280 companies in the Healthcare Providers & Services industry.
Is Painchek's 5-Year Yield-on-Cost % too high?
Painchek's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Painchek ranks #999999 out of 280 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Painchek has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's 5-Year Yield-on-Cost % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #999999 out of 280 companies for 5-Year Yield-on-Cost %. This places Painchek in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.94, based on 280 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Painchek and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.11 — trading 72.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Painchek's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Painchek (ASX:PCK), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Painchek (ASX:PCK) Overvalued in 2026?

Based on GuruFocus' analysis, Painchek stock appears to be undervalued. The current stock price of A$0.11 is trading 72.5% below its estimated GF Value™ of A$0.40. GuruFocus considers Painchek to be Possible Value Trap.

Key valuation signals for ASX:PCK:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: A$0.40 vs. price of A$0.11 (72.5% below fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Painchek Business Description

Address 35 Lime Street, Suite 401, Sydney, NSW, AUS, 2000
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
50GF Score

Get the complete analysis for ASX:PCK

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.40
GF Value